DE1115350B
(de)
|
1959-04-17 |
1961-10-19 |
Siemens Ag |
Selbstschalter, insbesondere Leitungsschutz-schalter, mit einem aus einem Kniegelenk bestehenden Antriebsmechanismus fuer das Schaltorgan
|
GB971307A
(en)
|
1961-03-02 |
1964-09-30 |
Wellcome Found |
5-anilinopyrimidines
|
GB1127875A
(en)
|
1967-03-23 |
1968-09-18 |
Parke Davis & Co |
4-(5-nitro-2-furyl) thiazolyl hydantoins and hydrouracils
|
US3949002A
(en)
|
1970-11-13 |
1976-04-06 |
Imperial Chemical Industries Limited |
Process for producing sulfone containing thiophenols
|
US3818024A
(en)
|
1972-02-16 |
1974-06-18 |
Velsicol Chemical Corp |
Benzothiazol substituted thiadiazolidines
|
CH565887A5
(es)
|
1972-08-22 |
1975-08-29 |
Ciba Geigy Ag |
|
US3939122A
(en)
|
1973-04-11 |
1976-02-17 |
Bayer Aktiengesellschaft |
Process for the preparation of compounds which contain hydantoin rings
|
FR2337554A1
(fr)
|
1976-01-08 |
1977-08-05 |
Buzas Andre |
Nouveaux derives de la pyrazolidinedione
|
JPS5915247B2
(ja)
|
1976-09-14 |
1984-04-09 |
古河電気工業株式会社 |
電力制御による走行体の定位置停止方式
|
US4093624A
(en)
|
1977-01-31 |
1978-06-06 |
Icn Pharmaceuticals, Inc. |
1,2,4-Thiadiazolidine-3,5-dione
|
FR2396549A2
(fr)
|
1977-07-06 |
1979-02-02 |
Buzas Andre |
Nouveaux derives de la pyrazolidinedione
|
US4256758A
(en)
|
1979-06-11 |
1981-03-17 |
Merck & Co., Inc. |
4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
US4296237A
(en)
|
1979-09-11 |
1981-10-20 |
Merck & Co., Inc. |
4-(Pyridyl, piperazinyl and thiazolyl substituted thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
|
US4298743A
(en)
|
1979-09-11 |
1981-11-03 |
Merck & Co., Inc. |
4-(Substituted phenyl thiazolyl)-3-hydroxy-3-pyrroline-2,5-diones
|
US4432992A
(en)
|
1979-11-05 |
1984-02-21 |
Merck & Co., Inc. |
4-[5(and 4)-Substituted-2-thienyl]-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
US4366189A
(en)
|
1979-12-21 |
1982-12-28 |
Ciba-Geigy Corporation |
4-Heterocyclyl-4'-vinylstilbenes
|
JPS59177557A
(ja)
|
1983-03-28 |
1984-10-08 |
Fuji Photo Film Co Ltd |
ハロゲン化銀カラ−写真感光材料
|
DE3406329A1
(de)
|
1984-02-22 |
1985-08-22 |
Merck Patent Gmbh, 6100 Darmstadt |
Pyridone
|
US4816454A
(en)
|
1984-09-21 |
1989-03-28 |
Cassella Aktiengesellschaft |
4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
|
US5514691A
(en)
|
1993-05-20 |
1996-05-07 |
Immunopharmaceutics, Inc. |
N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5103014A
(en)
|
1987-09-30 |
1992-04-07 |
American Home Products Corporation |
Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
|
AU606808B2
(en)
|
1988-06-29 |
1991-02-14 |
Otsuka Pharmaceutical Factory, Inc. |
Arylcarboxamide substituted by alkylphosphonates, process for preparing the same and a pharmaceutical composition containing the same
|
FR2662162B1
(fr)
|
1990-05-18 |
1995-01-20 |
Adir |
Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
|
GB9012936D0
(en)
|
1990-06-11 |
1990-08-01 |
Fujisawa Pharmaceutical Co |
Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
|
US5254715A
(en)
|
1990-11-07 |
1993-10-19 |
Warner-Lambert Company |
Aminosulfonyl carbamates
|
CA2078790C
(en)
|
1991-01-21 |
1998-10-06 |
Susumu Kamata |
3-benzylidene-1-carbamoyl-2-pyrrolidone analogues
|
US5162360A
(en)
|
1991-06-24 |
1992-11-10 |
Warner-Lambert Company |
2-heteroatom containing urea and thiourea ACAT inhibitors
|
GB9816837D0
(en)
|
1998-08-04 |
1998-09-30 |
Zeneca Ltd |
Amide derivatives
|
GB9125515D0
(en)
|
1991-11-29 |
1992-01-29 |
Merck Sharp & Dohme |
Therapeutic agents
|
US5658924A
(en)
|
1992-12-01 |
1997-08-19 |
The Green Cross Corporation |
1,8-naphthyridin-2-one derivative and use thereof
|
DE4302702A1
(de)
|
1993-02-01 |
1994-08-04 |
Bayer Ag |
Arylaminosulfonylharnstoffe
|
WO1994021617A1
(en)
|
1993-03-19 |
1994-09-29 |
Dowelanco |
A process for preparing halogenated isothiazoles
|
WO1994022872A1
(en)
|
1993-03-30 |
1994-10-13 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Cell adhesion inhibitor and thienotriazolodiazepine compound
|
WO1994024095A1
(en)
|
1993-04-16 |
1994-10-27 |
Abbott Laboratories |
Immunosuppressive agents
|
CA2123728A1
(en)
|
1993-05-21 |
1994-11-22 |
Noriyoshi Sueda |
Urea derivatives and their use as acat inhibitors
|
WO1995006044A1
(en)
|
1993-08-20 |
1995-03-02 |
Smithkline Beecham Plc |
Amide and urea derivatives as 5ht1d receptor antagonists
|
DE4337847A1
(de)
|
1993-11-05 |
1995-05-11 |
Bayer Ag |
Substituierte Phenylaminosulfonylharnstoffe
|
WO1995015954A1
(en)
|
1993-12-07 |
1995-06-15 |
Smithkline Beecham Plc |
Heterocyclic biphenylylamides useful as 5ht1d antagonists
|
DE4343831A1
(de)
|
1993-12-22 |
1995-06-29 |
Magyar Tudomanyos Akademia |
Substituierte Sulfonylharnstoffe
|
FR2715155B1
(fr)
|
1994-01-19 |
1996-07-26 |
Mayoly Spindler |
Inhibiteurs de la monoamine oxydase B et leurs procédés de préparation.
|
DE4414840A1
(de)
|
1994-04-28 |
1995-11-02 |
Bayer Ag |
Substituierte Phenylaminosulfonylharnstoffe
|
ATE360617T1
(de)
|
1994-06-15 |
2007-05-15 |
Otsuka Pharma Co Ltd |
Benzoheterocyclische verbindungen verwendbar als vasopressin- oder oxytocin-modulatoren
|
ATE235471T1
(de)
|
1994-11-24 |
2003-04-15 |
Basilea Pharmaceutica Ag |
Neue benzylpyrimidine
|
US5494925A
(en)
|
1994-12-02 |
1996-02-27 |
Sterling Winthrop Inc. |
2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
|
ES2153907T3
(es)
|
1994-12-22 |
2001-03-16 |
Smithkline Beecham Plc |
Compuestos espiro tetraciclicos, procedimiento para su preparacion y su uso como antagonistas del receptor 5ht1d.
|
CN1151147C
(zh)
|
1995-02-02 |
2004-05-26 |
史密丝克莱恩比彻姆有限公司 |
作为5-ht受体拮抗剂的吲哚衍生物
|
KR100423818B1
(ko)
|
1995-04-24 |
2004-07-05 |
가부시키가이샤 한도오따이 에네루기 켄큐쇼 |
액정화합물및이를함유하는액정조성물
|
US6123964A
(en)
*
|
1995-10-27 |
2000-09-26 |
Merck & Co., Inc. |
Wet granulation formulation of a growth hormone secretagogue
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
GB9605945D0
(en)
|
1996-03-21 |
1996-05-22 |
Smithkline Beecham Plc |
Novel compounds
|
GB9607219D0
(en)
|
1996-04-04 |
1996-06-12 |
Smithkline Beecham Plc |
Novel compounds
|
CN1515248A
(zh)
|
1996-04-23 |
2004-07-28 |
��̩��˹ҩ��ɷ�����˾ |
用作肌苷-5'-一磷酸脱氢酶抑制剂的脲衍生物
|
US6147088A
(en)
|
1996-05-20 |
2000-11-14 |
Merck & Co., Inc. |
Antagonists of gonadotropin releasing hormone
|
WO1997045400A1
(en)
|
1996-05-24 |
1997-12-04 |
Neurosearch A/S |
Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
|
GB9623833D0
(en)
|
1996-11-16 |
1997-01-08 |
Zeneca Ltd |
Chemical compound
|
US6020357A
(en)
|
1996-12-23 |
2000-02-01 |
Dupont Pharmaceuticals Company |
Nitrogen containing heteroaromatics as factor Xa inhibitors
|
ATE230742T1
(de)
|
1997-03-27 |
2003-01-15 |
Great Lakes Chemical Europ |
2-(2'-hydroxphenyl)-benzotriazole und ihre verwendung als lichtschutzmittel für organische polymere
|
US6187799B1
(en)
|
1997-05-23 |
2001-02-13 |
Onyx Pharmaceuticals |
Inhibition of raf kinase activity using aryl ureas
|
PT1019040E
(pt)
|
1997-05-23 |
2005-01-31 |
Bayer Pharmaceuticals Corp |
Inibicao da actividade de p38-quinase por meio de arilureias
|
US6235786B1
(en)
|
1997-08-06 |
2001-05-22 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
US6294573B1
(en)
|
1997-08-06 |
2001-09-25 |
Abbott Laboratories |
Reverse hydroxamate inhibitors of matrix metalloproteinases
|
NZ502702A
(en)
|
1997-09-23 |
2002-10-25 |
Astrazeneca Ab |
Amide derivatives for the treatment of diseases mediated by TNF, IL-1, IL-6 or IL-8
|
IT1295933B1
(it)
|
1997-10-30 |
1999-05-28 |
Great Lakes Chemical Italia |
2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
|
EP1028953A1
(en)
|
1997-11-03 |
2000-08-23 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
IL136738A0
(en)
|
1997-12-22 |
2001-06-14 |
Bayer Ag |
Inhibition of p38 kinase activity using substituted heterocyclic ureas
|
DE69836563T2
(de)
|
1997-12-22 |
2007-05-16 |
Bayer Pharmaceuticals Corp., West Haven |
INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN
|
US20070244120A1
(en)
|
2000-08-18 |
2007-10-18 |
Jacques Dumas |
Inhibition of raf kinase using substituted heterocyclic ureas
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
TR200002617T2
(tr)
|
1997-12-22 |
2000-11-21 |
Bayer Corporation |
Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
|
US20080300281A1
(en)
|
1997-12-22 |
2008-12-04 |
Jacques Dumas |
Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
|
BR9814374B1
(pt)
|
1997-12-22 |
2013-09-17 |
|
"urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
|
NZ333399A
(en)
|
1997-12-24 |
2000-05-26 |
Sankyo Co |
Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
|
SI0928790T1
(en)
|
1998-01-02 |
2003-06-30 |
F. Hoffmann-La Roche Ag |
Thiazole derivatives
|
JPH11209350A
(ja)
|
1998-01-26 |
1999-08-03 |
Eisai Co Ltd |
含窒素複素環誘導体およびその医薬
|
EP0956855B1
(en)
|
1998-04-24 |
2003-03-12 |
K.U. Leuven Research & Development |
Immunosuppressive effects of 8 substituted xanthine derivatives
|
PT1077931E
(pt)
|
1998-05-15 |
2005-03-31 |
Astrazeneca Ab |
Derivados de bezamida para o tratamento de doencas mediadas por citocinas
|
US6197599B1
(en)
|
1998-07-30 |
2001-03-06 |
Guorong Chin |
Method to detect proteins
|
AU753360B2
(en)
|
1998-07-31 |
2002-10-17 |
Nippon Soda Co., Ltd. |
Phenylazole compounds, process for producing the same and drugs for hyperlipemia
|
US6455520B1
(en)
|
1998-09-25 |
2002-09-24 |
Astra Zeneca Ab |
Benzamide derivatives and their use as cytokine inhibitors
|
DE69922526T2
(de)
|
1998-10-08 |
2005-06-02 |
Smithkline Beecham Plc, Brentford |
3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
|
GB9823873D0
(en)
|
1998-10-30 |
1998-12-30 |
Pharmacia & Upjohn Spa |
2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
HUP0202248A3
(en)
|
1999-03-12 |
2006-06-28 |
Boehringer Ingelheim Pharma |
Compounds useful as anti-inflammatory agents
|
JP2000275886A
(ja)
|
1999-03-23 |
2000-10-06 |
Konica Corp |
電子写真感光体、それを用いたプロセスカートリッジ及び画像形成装置
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
US6410254B1
(en)
|
1999-05-18 |
2002-06-25 |
Cytokinetics |
Compositions and assays utilizing ADP or phosphate for detecting protein modulators
|
AU5283600A
(en)
|
1999-05-24 |
2000-12-12 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
JP3972163B2
(ja)
|
1999-06-18 |
2007-09-05 |
株式会社大塚製薬工場 |
ホスホン酸ジエステル誘導体
|
NZ517694A
(en)
|
1999-08-13 |
2005-03-24 |
Vertex Pharma |
Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
|
AR035016A1
(es)
|
1999-08-25 |
2004-04-14 |
Takeda Chemical Industries Ltd |
Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6906063B2
(en)
|
2000-02-04 |
2005-06-14 |
Portola Pharmaceuticals, Inc. |
Platelet ADP receptor inhibitors
|
GB0008264D0
(en)
|
2000-04-04 |
2000-05-24 |
Smithkline Beecham Plc |
Novel method and compounds
|
US6500628B1
(en)
|
2000-05-25 |
2002-12-31 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules encoding human kinase and phosphatase homologues and uses therefor
|
WO2001096298A2
(en)
|
2000-06-14 |
2001-12-20 |
Warner-Lambert Company |
1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
|
EP1296977A1
(en)
|
2000-06-23 |
2003-04-02 |
Bristol-Myers Squibb Pharma Company |
Heteroaryl-phenyl substituted factor xa inhibitors
|
AU2001277723A1
(en)
|
2000-08-11 |
2002-02-25 |
Nippon Chemiphar Co., Ltd. |
Ppardelta activators
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
US20020173507A1
(en)
|
2000-08-15 |
2002-11-21 |
Vincent Santora |
Urea compounds and methods of uses
|
WO2002026712A2
(en)
|
2000-09-29 |
2002-04-04 |
Millennium Pharmaceuticals, Inc. |
Quaternary amines and related inhibitors of factor xa
|
IL155196A0
(en)
|
2000-10-05 |
2003-11-23 |
Fujisawa Pharmaceutical Co |
Benzamide derivatives and pharmaceutical compositions containing the same
|
WO2002060869A2
(en)
|
2000-10-19 |
2002-08-08 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of inflammation-enhanced cough
|
RU2301066C2
(ru)
|
2000-10-27 |
2007-06-20 |
Новартис Аг |
Лечение желудочно-кишечных стромальных опухолей
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
JP2002226464A
(ja)
|
2001-01-30 |
2002-08-14 |
Sumitomo Pharmaceut Co Ltd |
トリアリール類縁体およびその利用
|
JP2004518739A
(ja)
|
2001-02-15 |
2004-06-24 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤として有用なヘテロアリール置換尿素化合物の合成方法
|
US20030165873A1
(en)
|
2001-03-02 |
2003-09-04 |
Come Jon H. |
Three hybrid assay system
|
DE60219793T2
(de)
|
2001-07-11 |
2008-01-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
|
EP1281399A3
(en)
|
2001-08-01 |
2004-02-11 |
Warner-Lambert Company |
Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production
|
EP1427412A1
(en)
|
2001-09-13 |
2004-06-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating cytokine mediated diseases
|
MXPA04005137A
(es)
|
2001-12-03 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuestos de aril urea en combinacion con otros agentes citostaticos para el tratamiento de canceres humanos.
|
AU2002360763A1
(en)
|
2001-12-19 |
2003-07-09 |
Atherogenics, Inc. |
Chalcone derivatives and their use to treat diseases
|
US20050090474A1
(en)
|
2002-01-16 |
2005-04-28 |
Zvi Naor |
Methods and compositions for enhancing and inhibiting fertilization
|
WO2003063822A2
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
|
MXPA04007435A
(es)
|
2002-02-01 |
2004-10-11 |
Pfizer Prod Inc |
Metodo para preparar dispersiones solidas amorfas de farmacos secadas por pulverizacion utilizando inyectores a presion.
|
AU2003209119A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
WO2003068223A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
CA2473634C
(en)
|
2002-02-25 |
2011-11-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
AU2003210305B2
(en)
|
2002-02-28 |
2006-07-06 |
F. Hoffmann-La Roche Ag |
Thiazole derivatives as NPY receptor antagonists
|
US6995144B2
(en)
|
2002-03-14 |
2006-02-07 |
Eisai Co., Ltd. |
Nitrogen containing heterocyclic compounds and medicines containing the same
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
JP2005538975A
(ja)
|
2002-07-03 |
2005-12-22 |
アステックス テクノロジー リミテッド |
p38MAPキナーゼ阻害薬としての3−(ヘテロ)アリールメトキシピリジン類およびそれらの類縁体
|
US20040138216A1
(en)
|
2002-12-23 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
|
US7279576B2
(en)
|
2002-12-31 |
2007-10-09 |
Deciphera Pharmaceuticals, Llc |
Anti-cancer medicaments
|
US20040171075A1
(en)
|
2002-12-31 |
2004-09-02 |
Flynn Daniel L |
Modulation of protein functionalities
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
US20080045706A1
(en)
|
2002-12-31 |
2008-02-21 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
WO2005024755A2
(en)
|
2002-12-31 |
2005-03-17 |
Deciphera Pharmaceuticals, Llc. |
Medicaments for the treatment of neurodegenerative disorders or diabetes
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
JP4927533B2
(ja)
|
2003-02-28 |
2012-05-09 |
ニッポネックス インコーポレイテッド |
癌その他の疾患の治療に有用な置換ピリジン誘導体
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
MXPA05009103A
(es)
|
2003-02-28 |
2006-04-18 |
Bayer Pharmaceuticals Corp |
Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
|
US20050014753A1
(en)
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
WO2004113352A1
(en)
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
WO2005002673A1
(en)
|
2003-07-03 |
2005-01-13 |
Astex Therapeutics Limited |
Raf kinase inhibitors
|
US8754238B2
(en)
|
2003-07-22 |
2014-06-17 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
EP1673343A4
(en)
|
2003-10-08 |
2008-09-10 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
|
US20050197371A1
(en)
|
2003-11-13 |
2005-09-08 |
Ambit Biosciences Corporation |
Urea derivatives as PDGFR modulators
|
US20070191336A1
(en)
|
2003-12-24 |
2007-08-16 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
US20080220497A1
(en)
|
2003-12-24 |
2008-09-11 |
Flynn Daniel L |
Modulation of protein functionalities
|
ATE548353T1
(de)
|
2004-03-23 |
2012-03-15 |
Arena Pharm Inc |
Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
|
MXPA06012394A
(es)
|
2004-04-30 |
2007-01-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
|
EP1773826A4
(en)
|
2004-07-02 |
2009-06-03 |
Exelixis Inc |
MODULATORS OF C-MET AND THEIR METHOD OF USE
|
EP1786422A2
(en)
|
2004-08-16 |
2007-05-23 |
Prosidion Limited |
Aryl urea derivatives for treating obesity
|
US7888364B2
(en)
|
2004-09-02 |
2011-02-15 |
Curis, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
US8003657B2
(en)
|
2004-10-13 |
2011-08-23 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives
|
WO2006046552A1
(ja)
|
2004-10-27 |
2006-05-04 |
Toyama Chemical Co., Ltd. |
新規な含窒素複素環化合物およびその塩
|
GT200500321A
(es)
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
WO2006081034A2
(en)
|
2004-12-23 |
2006-08-03 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
EP1835934A4
(en)
|
2004-12-23 |
2010-07-28 |
Deciphera Pharmaceuticals Llc |
ENZYME MODULATORS AND TREATMENTS
|
GB0500435D0
(en)
|
2005-01-10 |
2005-02-16 |
Novartis Ag |
Organic compounds
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
AU2006206687A1
(en)
|
2005-01-19 |
2006-07-27 |
Arena Pharmaceuticals, Inc. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
|
AR052886A1
(es)
|
2005-01-26 |
2007-04-11 |
Arena Pharm Inc |
Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
|
US9265731B2
(en)
|
2005-01-28 |
2016-02-23 |
Bend Research, Inc. |
Drying of drug-containing particles
|
BRPI0608252A2
(pt)
|
2005-03-10 |
2010-04-06 |
Cgi Pharmaceuticals Inc |
entidades quìmicas, composições farmacêuticas compreendendo as mesmas, métodos utilizando as referidas entidades quìmicas e uso das referidas entidades quìmicas
|
DE102005015253A1
(de)
|
2005-04-04 |
2006-10-05 |
Merck Patent Gmbh |
Pyrazolderivate
|
AU2006301458A1
(en)
|
2005-10-13 |
2007-04-19 |
Devgen N.V. |
Kinase inhibitors
|
CA2631746A1
(en)
|
2005-12-01 |
2007-06-07 |
Bayer Healthcare Llc |
Urea compounds useful in the treatment of cancer
|
TW200804349A
(en)
|
2005-12-23 |
2008-01-16 |
Kalypsys Inc |
Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
|
JP2009522363A
(ja)
|
2006-01-04 |
2009-06-11 |
ローカス ファーマシューティカルズ、インク. |
プロテインキナーゼの阻害剤
|
US20090124633A1
(en)
|
2006-04-12 |
2009-05-14 |
Alfred Jonczyk |
N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
|
CA2649994A1
(en)
|
2006-04-26 |
2007-11-08 |
Cancer Research Technology Limited |
Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
|
US20090312321A1
(en)
|
2006-05-15 |
2009-12-17 |
Irm Llc |
Compositions and methods for fgf receptor kinases inhibitors
|
WO2007137107A2
(en)
|
2006-05-19 |
2007-11-29 |
Abbott Laboratories |
Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
|
WO2008033858A2
(en)
|
2006-09-11 |
2008-03-20 |
Cgi Pharmaceuticals, Inc. |
Kinase inhibitors, and methods of using and identifying kinase inhibitors
|
US8188113B2
(en)
|
2006-09-14 |
2012-05-29 |
Deciphera Pharmaceuticals, Inc. |
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
CN101553232A
(zh)
|
2006-09-14 |
2009-10-07 |
迪赛孚尔制药有限公司 |
用于治疗增殖性疾病的激酶抑制剂
|
US7897762B2
(en)
|
2006-09-14 |
2011-03-01 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of proliferative diseases
|
US7790756B2
(en)
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
US20120225057A1
(en)
|
2006-10-11 |
2012-09-06 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
AU2007309279B2
(en)
|
2006-10-20 |
2011-03-24 |
Irm Llc |
Compositions and methods for modulating c-kit and PDGFR receptors
|
US20080248487A1
(en)
|
2007-04-09 |
2008-10-09 |
Flynn Daniel L |
Modulation of protein functionalities
|
US20080248548A1
(en)
|
2007-04-09 |
2008-10-09 |
Flynn Daniel L |
Modulation of protein functionalities
|
PL2139484T3
(pl)
|
2007-04-10 |
2013-12-31 |
Exelixis Inc |
Sposoby leczenia raka z zastosowaniem pirydopirymidynonów jako inhibitorów PI3K alfa
|
US20110189167A1
(en)
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
CA2678639A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
BRPI0816320A2
(pt)
|
2007-09-04 |
2015-03-24 |
Biolipox Ab |
Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação
|
US8389567B2
(en)
|
2007-12-12 |
2013-03-05 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
CN102083828B
(zh)
|
2008-02-22 |
2013-11-13 |
Irm责任有限公司 |
作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
|
JP2011513339A
(ja)
|
2008-03-05 |
2011-04-28 |
9222−9129 ケベック インコーポレイテッド |
タンパク質チロシンキナーゼ活性の阻害剤
|
US20090281089A1
(en)
|
2008-04-11 |
2009-11-12 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
EP2274280A2
(en)
|
2008-04-16 |
2011-01-19 |
Biolipox AB |
Bis-aryl compounds for use as medicaments
|
US20110112193A1
(en)
|
2008-05-14 |
2011-05-12 |
Peter Nilsson |
Bis-aryl compounds for use as medicaments
|
WO2010011837A1
(en)
|
2008-07-24 |
2010-01-28 |
Bristol-Myers Squibb Company |
Fused heterocyclic compounds useful as kinase modulators
|
EA201170627A1
(ru)
|
2008-10-29 |
2011-10-31 |
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Циклопропанамиды и аналоги, проявляющие противораковые и антипролиферативные активности
|
US9724664B2
(en)
|
2009-03-27 |
2017-08-08 |
Bend Research, Inc. |
Spray-drying process
|
US8669289B2
(en)
|
2009-04-24 |
2014-03-11 |
The Jackson Laboratory |
Methods and compositions relating to hematologic malignancies
|
AU2010249790A1
(en)
|
2009-05-22 |
2011-12-08 |
Exelixis, Inc. |
Benzoxazepines based P13K/mT0R inhibitors against proliferative diseases
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
US20110237563A1
(en)
|
2010-03-23 |
2011-09-29 |
Dominique Costantini |
Fast dissolving drug delivery systems
|
WO2011123788A1
(en)
|
2010-04-01 |
2011-10-06 |
Duke University |
Compositions and methods for the treatment of cancer
|
US8569319B2
(en)
|
2010-04-29 |
2013-10-29 |
Deciphera Pharmaceuticals, LLS |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
RU2012151012A
(ru)
|
2010-04-29 |
2014-06-10 |
ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием
|
US9296722B2
(en)
|
2010-05-27 |
2016-03-29 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
JP5789259B2
(ja)
|
2010-07-16 |
2015-10-07 |
協和発酵キリン株式会社 |
含窒素芳香族複素環誘導体
|
WO2012035131A1
(en)
|
2010-09-16 |
2012-03-22 |
University Of Zurich |
Treatment of abl overexpressing b-cell lymphoma
|
WO2012040502A1
(en)
|
2010-09-24 |
2012-03-29 |
Bend Research, Inc. |
High-temperature spray drying process and apparatus
|
US20140147415A1
(en)
|
2010-11-05 |
2014-05-29 |
Ab Science |
Treatment of mastocytosis with masitinib
|
EA201390766A1
(ru)
|
2010-11-24 |
2013-11-29 |
Экселиксис, Инк. |
БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
|
US20130288984A1
(en)
|
2011-01-11 |
2013-10-31 |
Glaxosmithkline Llc |
Combination
|
AU2012240240A1
(en)
|
2011-04-04 |
2013-05-09 |
Netherlands Cancer Institute |
Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
|
CN102731385A
(zh)
|
2011-04-08 |
2012-10-17 |
湖南有色凯铂生物药业有限公司 |
3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用
|
CA2843417C
(en)
|
2011-07-29 |
2018-08-21 |
Medivation Prostate Therapeutics, Inc. |
Treatment of breast cancer
|
WO2013036232A2
(en)
|
2011-09-08 |
2013-03-14 |
Deciphera Pharmaceuticals, Llc |
Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
ES2650608T3
(es)
*
|
2011-10-14 |
2018-01-19 |
Array Biopharma, Inc. |
Dispersión sólida
|
WO2013078295A2
(en)
|
2011-11-22 |
2013-05-30 |
Deciphera Pharmaceuticals, Llc |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
KR101338510B1
(ko)
|
2011-12-09 |
2013-12-11 |
포항공과대학교 산학협력단 |
아미노퀴놀론 화합물을 포함하는 간염, 간경변, 또는 간암의 예방 또는 치료용 의약 조성물
|
AR090151A1
(es)
|
2012-03-07 |
2014-10-22 |
Lilly Co Eli |
Compuestos inhibidores de raf
|
US9187474B2
(en)
|
2012-03-07 |
2015-11-17 |
Deciphera Pharmaceuticals, Llc |
Raf inhibitor compounds
|
UA122044C2
(uk)
*
|
2012-03-23 |
2020-09-10 |
Еррей Біофарма Інк. |
Лікування раку головного мозку
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
WO2013177420A2
(en)
|
2012-05-23 |
2013-11-28 |
St. Jude Children's Research Hospital |
Methods and compositions for the treatment of bcr-abl positive lymphoblastic leukemias
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
CA2875970C
(en)
|
2012-06-07 |
2017-07-04 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
WO2014015056A2
(en)
|
2012-07-17 |
2014-01-23 |
Washington University |
Anti-mucus drugs and uses therefor
|
JP2015530378A
(ja)
|
2012-08-29 |
2015-10-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
変形性関節症の処置のためのddr2インヒビター
|
EP2890815B1
(en)
|
2012-08-31 |
2019-03-20 |
The Regents of the University of Colorado |
Methods for diagnosis and treatment of cancer
|
AU2013311705A1
(en)
|
2012-09-10 |
2015-02-05 |
F. Hoffmann-La Roche Ag |
6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
|
WO2014040242A1
(zh)
|
2012-09-12 |
2014-03-20 |
湖南有色凯铂生物药业有限公司 |
3-氯-及3-甲氧基-n-甲基-2-吡啶酰胺化合物及其作为抗癌药物的应用
|
CN103664787B
(zh)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
炔杂芳环化合物及其应用
|
US20150275306A1
(en)
|
2012-10-10 |
2015-10-01 |
Stichting Het Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis |
Methods and means for predicting resistance to anti-cancer treatment
|
FR3000493A1
(fr)
|
2012-12-28 |
2014-07-04 |
Oribase Pharma |
Nouveaux inhibiteurs de proteines kinases
|
FR3000492B1
(fr)
|
2012-12-28 |
2015-09-11 |
Oribase Pharma |
Nouveaux derives azaindole en tant qu'inhibiteurs multikinases
|
EP2968536B1
(en)
|
2013-03-13 |
2023-06-28 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Methods for modulating chemotherapeutic cytotoxicity
|
CN104045642B
(zh)
|
2013-03-14 |
2016-08-24 |
上海医药工业研究院 |
含嘧啶或吡啶的稠环化合物及其作为抗肿瘤药物的应用
|
US9012635B2
(en)
|
2013-03-15 |
2015-04-21 |
Deciphera Pharmaceuticals, Llc |
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
WO2014145015A2
(en)
|
2013-03-15 |
2014-09-18 |
Deciphera Pharmaceuticals, Llc |
Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
|
WO2014145029A2
(en)
|
2013-03-15 |
2014-09-18 |
Deciphera Pharmaceuticals, Llc |
N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
AU2014233414B2
(en)
|
2013-03-15 |
2018-07-12 |
Deciphera Pharmaceuticals, Llc. |
N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
US9193719B2
(en)
|
2013-03-15 |
2015-11-24 |
Deciphera Pharmaceuticals, Llc |
1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
|
MX365574B
(es)
|
2013-03-15 |
2019-06-06 |
Deciphera Pharmaceuticals Llc |
2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.
|
US20160101106A1
(en)
|
2013-05-07 |
2016-04-14 |
Inhibikase Therapeutics, Inc. |
Methods for treating hcv infection
|
FR3008979B1
(fr)
|
2013-07-23 |
2015-07-24 |
Servier Lab |
Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US10111897B2
(en)
|
2013-10-03 |
2018-10-30 |
Duke University |
Compositions and methods for treating cancer with JAK2 activity
|
WO2015069217A1
(en)
|
2013-11-05 |
2015-05-14 |
Baylor College Of Medicine |
Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
|
US9457019B2
(en)
|
2013-11-07 |
2016-10-04 |
Deciphera Pharmaceuticals, Llc |
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
KR20160070188A
(ko)
|
2013-11-07 |
2016-06-17 |
데시페라 파마슈티칼스, 엘엘씨. |
암치료에 유용한 tie2 키나아제의 억제 방법
|
WO2015076213A1
(ja)
|
2013-11-22 |
2015-05-28 |
独立行政法人国立成育医療研究センター |
急性リンパ芽球性白血病の新規キメラ遺伝子atf7ip-pdgfrb
|
WO2015092423A1
(en)
|
2013-12-20 |
2015-06-25 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
WO2015106292A1
(en)
|
2014-01-13 |
2015-07-16 |
Coferon, Inc. |
Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same
|
WO2015106294A1
(en)
|
2014-01-13 |
2015-07-16 |
Coferon,Inc. |
Bivalent bcr-abl tyrosine kinase ligands, and methods of using same
|
CA2944043A1
(en)
|
2014-03-25 |
2015-10-01 |
University Of Utah Research Foundation |
Peptide inhibitors of bcr-abl oligomerization
|
WO2015184443A1
(en)
|
2014-05-30 |
2015-12-03 |
The Regents Of The University Of Colorado |
Activating ntrk1 gene fusions predictive of kinase inhibitor therapy
|
BR112017002231A2
(pt)
|
2014-08-07 |
2018-07-17 |
Pharmacyclics Llc |
novas formulações de um inibidor de tirosina cinase de bruton
|
CN105461699B
(zh)
|
2014-09-25 |
2019-07-09 |
广东东阳光药业有限公司 |
取代的杂环化合物及其使用方法和用途
|
WO2016061231A1
(en)
|
2014-10-14 |
2016-04-21 |
Deciphera Pharmaceuticals, Llc |
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
EP3206752A1
(en)
|
2014-10-14 |
2017-08-23 |
Deciphera Pharmaceuticals, LLC |
Inhibition of trk kinase mediated tumor growth and disease progression
|
US20170360791A1
(en)
|
2014-12-04 |
2017-12-21 |
Astex Pharmaceuticals, Inc. |
Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
|
US20160166679A1
(en)
|
2014-12-12 |
2016-06-16 |
Purdue Research Foundation |
Method of treatment using folate conjugates and tyrosine kinase inhibitors
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
WO2016103223A1
(en)
|
2014-12-23 |
2016-06-30 |
Fratagene Therapeutics Ltd. |
Methods of treating friedreich's ataxia using src inhibitors
|
WO2016114322A1
(ja)
|
2015-01-13 |
2016-07-21 |
国立大学法人京都大学 |
筋萎縮性側索硬化症の予防及び/又は治療剤
|
US9637488B2
(en)
|
2015-01-29 |
2017-05-02 |
Fuqiang Ruan |
Heterocyclic compounds as inhibitors of class I PI3KS
|
WO2016135046A1
(en)
|
2015-02-24 |
2016-09-01 |
Academisch Medisch Centrum |
Inhibitors of raf1, mst1, and pkl1 for use in the treatment of a retrovirus
|
WO2016154524A1
(en)
|
2015-03-26 |
2016-09-29 |
Emory University |
Carbonic anhydrase inhibitors and uses related thereto
|
CA2987281A1
(en)
|
2015-05-29 |
2016-12-08 |
Ignyta, Inc. |
Compositions and methods for treating patients with rtk mutant cells
|
EP3120851A1
(en)
|
2015-07-21 |
2017-01-25 |
Pangaea Biotech S.L. |
4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
|
WO2017042944A1
(ja)
|
2015-09-10 |
2017-03-16 |
国立大学法人山梨大学 |
フィラデルフィア染色体陽性(Ph+)急性リンパ性白血病(ALL)の治療薬又は治療方法
|
KR20180097530A
(ko)
|
2015-11-02 |
2018-08-31 |
예일 유니버시티 |
단백질분해 표적화 키메라 화합물(Proteolysis Targeting Chimera compound) 및 그의 제조 및 사용 방법
|
CA3010101A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
CA3015753A1
(en)
|
2016-02-26 |
2017-08-31 |
Celgene Corporation |
Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
|
WO2017214514A1
(en)
|
2016-06-09 |
2017-12-14 |
Bioxcel Corporation |
Use of src family kinase inhibitor in ribosomal disorder
|
WO2018005737A1
(en)
|
2016-06-29 |
2018-01-04 |
The General Hospital Corporation |
Renal clearable organic nanocarriers
|
SI3513809T1
(sl)
|
2016-09-13 |
2022-07-29 |
Kyowa Kirin Co.,Ltd. |
Medicinski sestavek, ki vsebuje tivozanib
|
AU2017325844A1
(en)
|
2016-09-14 |
2019-03-07 |
Gilead Sciences, Inc. |
SYK inhibitors
|
TW201822764A
(zh)
|
2016-09-14 |
2018-07-01 |
美商基利科學股份有限公司 |
Syk抑制劑
|
US11932870B2
(en)
|
2016-12-05 |
2024-03-19 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
CN106822128A
(zh)
|
2017-02-24 |
2017-06-13 |
南华大学附属第医院 |
酪氨酸激酶抑制剂dcc‑2036的新应用
|
CA3060416A1
(en)
|
2017-04-21 |
2018-10-25 |
Epizyme, Inc. |
Combination therapies with ehmt2 inhibitors
|
US11802875B2
(en)
|
2017-05-30 |
2023-10-31 |
Albert Einstein College Of Medicine |
Method for treating neoadjuvant chemotherapy-induced metastasis
|
EP3630110A1
(en)
|
2017-05-30 |
2020-04-08 |
Deciphera Pharmaceuticals, Inc. |
Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptoralpha
|
BR112020007972A2
(pt)
*
|
2017-10-27 |
2020-10-20 |
Plexxikon, Inc. |
formulações de composto que modula quinases
|
CA3089630A1
(en)
|
2018-01-31 |
2019-08-08 |
Deciphera Pharmaceuticals, Llc |
Combination therapy for the treatment of mastocytosis
|
CN115192726A
(zh)
|
2018-04-03 |
2022-10-18 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
FI3902547T3
(fi)
|
2018-12-28 |
2023-12-05 |
Deciphera Pharmaceuticals Llc |
Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa
|
EP3938363A1
(en)
*
|
2019-03-11 |
2022-01-19 |
Teva Pharmaceuticals International GmbH |
Solid state forms of ripretinib
|
AU2020274011B2
(en)
|
2019-05-10 |
2024-02-15 |
Deciphera Pharmaceuticals, Llc |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
TW202108573A
(zh)
|
2019-05-10 |
2021-03-01 |
美商迪賽孚爾製藥有限公司 |
苯基胺基嘧啶醯胺自噬抑制劑及其使用方法
|
KR20220045189A
(ko)
|
2019-08-12 |
2022-04-12 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양을 치료하는 방법
|
WO2021030405A1
(en)
|
2019-08-12 |
2021-02-18 |
Deciphera Pharmaceuticals, Llc |
Ripretinib for treating gastrointestinal stromal tumors
|
CA3163051A1
(en)
|
2019-12-30 |
2021-07-08 |
Michael D. Kaufman |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
KR20220123057A
(ko)
|
2019-12-30 |
2022-09-05 |
데시페라 파마슈티칼스, 엘엘씨. |
비정질 키나아제 억제제 제형 및 이의 사용 방법
|
CN114902895B
(zh)
|
2022-04-06 |
2023-12-12 |
安徽科技学院 |
一种基于蔬菜种植的能源回收式大棚
|